All lobbying filings

EMPIRE CONSULTING GROUP

EMPIRE CONSULTING GROUP filed a Q3 report for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA on October 19, 2026, reporting $50,000 in lobbying income.

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Pharmaceuticals

All filings by EMPIRE CONSULTING GROUP · Everything PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

MFN drug pricing, 340B, PBM reform, and other drug pricing issues.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.